Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 20/20 | 0.78 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.78 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.78 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biricodar SCHEMBL7546702 | 0.88 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL29405867 | 0.88 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL154547 | 0.88 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL13038499 | 0.88 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL3672384 | 0.86 | FKBP1A (0.78) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL14401254 | 0.86 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL7129468 | 0.86 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL29393244 | 0.86 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL3677411 | 0.86 | FKBP1A (0.68) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL19719611 | 0.85 | FKBP1A (0.77) | FKBP1AFKBP4FKBP5ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227859-B1 | NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS | ALCON INC (CH) | 2006-08-09 | — | — | EP | claimed |
| EP-1666053-A1 | Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors | Vertex Pharmceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| EP-0754176-B1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMA (US) | 2001-12-05 | — | — | EP | claimed |
| US-5780484-A | Methods for stimulating neurite growth with piperidine compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | claimed |
| US-5744485-A | INCREASE SENSITIVITY OF CELLS; CANCER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-28 | — | — | US | claimed |
| US-7825136-B2 | Potentiators of antibacterial activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090291964-A1 | Potentiators of Antibacterial Activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-26 | — | — | US | disclosed |
| EP-1138673-B1 | Novel carbamates and ureas as modifiers of multi-drug resistance | VERTEX PHARMA (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| EP-0754176-B1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMA (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1138673-A2 | Novel carbamates and ureas as modifiers of multi-drug resistance | Vertex Pharmaceuticals Incorporated (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5780484-A | Methods for stimulating neurite growth with piperidine compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| US-5744485-A | INCREASE SENSITIVITY OF CELLS; CANCER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291964-A1 | Potentiators of Antibacterial Activity | SLC11A2, MPO, ABCB11 | FKBP1A 1960/4885FKBP4 2416/4885FKBP5 2372/4885 |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | TLR1, ABCB11, SLC7A1 | FKBP1A 2885/4885FKBP4 3274/4885FKBP5 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.